Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis

References

• Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet, 2005;365:331–340.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med, 2001;135:73–87.
   PubMed Web of Science ®Google Scholar
• Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol, 2007;18:1227–1238.
   PubMed Web of Science ®Google Scholar
• Wang WJ, Chang CH, Sun MF, Hsu SF, Weng CS. DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. PLoS One, 2014;9:e93447.
   PubMed Web of Science ®Google Scholar
• Hirakawa H, Zempo H, Ogawa M, et al. A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice. PLoS One, 2015;10:e0119360
   PubMed Web of Science ®Google Scholar
• Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation, 2011;124:2338–2349.
   PubMed Web of Science ®Google Scholar
• Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes, 2011;60:1246–1257.
   PubMed Web of Science ®Google Scholar
• Min HS, Kim JE, Lee MH, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest, 2014;94:598–607.
   PubMed Web of Science ®Google Scholar
• Yamada M, Oda T, Higashi K, et al. Involvement of epimorphin in the repair of experimental renal fibrosis in mice. Lab Invest, 2010;90:867–880.
   PubMed Web of Science ®Google Scholar
• Oda T, Jung YO, Kim HS, et al. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int, 2001;60:587–596.
   PubMed Web of Science ®Google Scholar
• Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol, 2012;23:1329–1338.
   PubMed Web of Science ®Google Scholar
• Takechi H, Oda T, Hotta O, et al. Clinical and immunological implications of increase in CD208+ dendritic cells in tonsils of patients with immunoglobulin A nephropathy. Nephrol Dial Transplant, 2013;28:3004–3013.
   PubMed Web of Science ®Google Scholar
• Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci, 2007;81:272–279.
   PubMed Web of Science ®Google Scholar
• Kushiyama T, Oda T, Yamamoto K, et al. Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease. Am J Physiol Renal Physiol, 2013;304:F1325–F1334.
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol, 2008;588:325332.
   Web of Science ®Google Scholar
• Kushiyama T, Oda T, Yamada M, et al. Alteration in the phenotype of macrophages in the repair of renal interstitial fibrosis in mice. Nephrology (Carlton), 2011;16:522–535.
   PubMed Web of Science ®Google Scholar
• Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm, 2010;2010:592760.
   PubMedGoogle Scholar
• Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology, 1993;80:465–470.
   PubMed Web of Science ®Google Scholar
• Ravidà A, Musante L, Kreivi M, et al. Glycosylation patterns of kidney proteins differ in rat diabetic nephropathy. Kidney Int, 2015;87:963–964.
   PubMed Web of Science ®Google Scholar
• Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes, 2011;60:1917–1925.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Ponzo V, Bo S. Effect of dipeptidyl peptidase-4 inhibitors on plasma adiponectin: A systematic review and meta-analysis of randomized controlled trials. Curr Med Chem, 2016;23:1356–1369.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Higashijima Y, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int, 2014;86:701–711.
   PubMed Web of Science ®Google Scholar
• Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol, 2015;308:F878–F887.
   PubMed Web of Science ®Google Scholar
• Katagiri D, Hamasaki Y, Doi K, et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol, 2013;24:2034–2043.
   PubMed Web of Science ®Google Scholar
• Du J, Zhang L, Wang Z, et al. Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol, Cell Physiol, 2016;310:C270–C283.
   PubMed Web of Science ®Google Scholar
• Gaspari T, Brdar M, Lee HW, et al. Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. Diab Vasc Dis Res, 2016;13:56–68.
   PubMed Web of Science ®Google Scholar